STOCK TITAN

CFO option grant at Aspira Women's Health (AWHL) totals 75,000 shares

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Aspira Women's Health Inc. reported that Chief Financial Officer John Strahley received a grant of employee stock options for 75,000 shares of common stock on June 16, 2026. The options have a $0.50 exercise price and expire on June 16, 2036. According to the vesting schedule, 18,750 options vest on July 26, 2026, with the remaining options vesting in equal monthly installments over the following nine months. No open-market purchases or sales were reported.

Positive

  • None.

Negative

  • None.
Insider Strahley John
Role Chief Financial Officer
Type Security Shares Price Value
Grant/Award Employee Stock Option (Right to Buy) F1 75,000 $0.00 $0.00
Holdings After Transaction: Employee Stock Option (Right to Buy) — 75,000 shares (Direct)
Footnotes (1)
  1. F1. 18,750 shares will vest on July 26, 2026. The remaining shares will vest in equal monthly installments over the next 9 months.
Stock options granted 75,000 shares Employee stock option grant to CFO John Strahley on June 16, 2026
Exercise price $0.50 per share Exercise price for the 75,000 employee stock options
Expiration date June 16, 2036 Expiration of CFO employee stock options
Initial vesting tranche 18,750 shares Options vesting on July 26, 2026
Remaining vesting period 9 months Remaining options vest in equal monthly installments after July 26, 2026
Employee Stock Option (Right to Buy) financial
"security_title: Employee Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 0.5000"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"18,750 shares will vest on July 26, 2026."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did Aspira Women's Health (AWHL) report for its CFO?

Aspira Women's Health reported a grant of 75,000 employee stock options to CFO John Strahley. The options relate to common stock, with an exercise price of $0.50 per share, reflecting routine equity-based executive compensation.

What is the exercise price of the CFO stock options at Aspira Women's Health (AWHL)?

The granted options carry an exercise price of $0.50 per share. This price applies to all 75,000 options awarded and represents the amount payable to acquire each share of common stock upon exercise.

How do the 75,000 stock options granted to AWHL's CFO vest over time?

Of the 75,000 options, 18,750 vest on July 26, 2026. The remaining options then vest in equal monthly installments over the subsequent nine months, creating a staggered vesting schedule tied to continued service.

When do the CFO stock options at Aspira Women's Health (AWHL) expire?

The granted employee stock options expire on June 16, 2036. After this date, any unexercised options become invalid, giving the CFO a roughly ten-year window to exercise vested options.

Did the Aspira Women's Health (AWHL) Form 4 show any stock sales or purchases by the CFO?

The Form 4 shows no open-market stock purchases or sales by the CFO. It reports only a compensatory grant of 75,000 employee stock options, classified as a grant, award, or other acquisition transaction.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Strahley John

(Last)(First)(Middle)
C/O ASPIRA WOMEN'S HEALTH INC.
12117 BEE CAVES RD, BLDG 3-100

(Street)
AUSTIN TEXAS 78738

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Aspira Women's Health Inc. [ AWHL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (Right to Buy)$0.506/16/2026A75,000 (1)06/16/2036Common Stock75,000$075,000D
Explanation of Responses:
1. 18,750 shares will vest on July 26, 2026. The remaining shares will vest in equal monthly installments over the next 9 months.
/s/ John Strahley07/15/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)